Chimeric antigen receptor (CAR) T-cell therapy use in patients with multiple myeloma and kidney failure on maintenance hemodialysis: A report of 2 cases Journal Article
| Authors: | Pak, W. L. W.; Brumwell, N. A.; Kabel, C. C.; Gutgarts, V.; Jaffer Sathick, I.; Mailankody, S.; Lesokhin, A. M.; Landau, H. J.; Shaikh, A. |
| Article Title: | Chimeric antigen receptor (CAR) T-cell therapy use in patients with multiple myeloma and kidney failure on maintenance hemodialysis: A report of 2 cases |
| Abstract: | Chimeric antigen receptor (CAR) T-cell therapy against B-cell maturation antigen is a new treatment modality for relapsed or refractory multiple myeloma (MM). Patients with kidney failure and MM were excluded from the pivotal CAR T-cell therapy clinical trials: KaRMMa (idecabtagene vicleucel) and CARTITUDE (ciltacabtagene autocleucel). The safety and efficacy of CAR T-cell therapy in patients with relapsed or refractory MM and kidney failure are limited to a few case reports using idecabtagene vicleucel. Here, we report the first 2 cases of ciltacabtagene autoleucel use in patients with kidney failure on maintenance hemodialysis and relapsed or refractory MM. Both patients achieved a hematologic response following ciltacabtagene autoleucel administration without serious adverse events. These findings suggest that ciltacabtagene autoleucel may be safe and effective in patients with relapsed or refractory MM and kidney failure. In this report, we review the available literature regarding the use of CAR T-cell therapy in patients with MM and kidney failure. We also discuss the modification of the lymphodepletion regimen in the kidney failure setting. © 2024 The Authors |
| Keywords: | adult; clinical article; aged; middle aged; fludarabine; lenalidomide; cancer recurrence; case report; drug efficacy; drug safety; drug withdrawal; cancer staging; neurotoxicity; outcome assessment; bortezomib; multiple myeloma; maintenance therapy; cyclophosphamide; dexamethasone; kidney failure; hematopoietic stem cell transplantation; bone marrow biopsy; blood transfusion; drug substitution; hemodialysis; disease exacerbation; kidney biopsy; carfilzomib; pomalidomide; cellular therapy; refractory disease; very elderly; human; male; female; article; daratumumab; chimeric antigen receptor t-cell immunotherapy; lymphodepletion; ciltacabtagene autoleucel; idecabtagene vicleucel; end-stage kidney disease; t cell depletion therapy |
| Journal Title: | Kidney Medicine |
| Volume: | 6 |
| Issue: | 8 |
| ISSN: | 2590-0595 |
| Publisher: | Elsevier Ltd |
| Date Published: | 2024-08-01 |
| Start Page: | 100856 |
| Language: | English |
| DOI: | 10.1016/j.xkme.2024.100856 |
| PROVIDER: | scopus |
| PMCID: | PMC11295848 |
| PUBMED: | 39100867 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Group (P30 CA008748) acknowledged in PDF -- MSK corresponding author is Aisha Shaikh -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work